Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...

Switching from etravirine- to doravirine-containing regimen maintains viral suppression in people with HIV-1 infection, including those with archived resistance to NNRTIs.

The investigational oral therapy combines doravirine, a non-nucleoside reverse transcriptase inhibitor, with islatravir, a nucleoside reverse transcriptase translocation inhibitor, in a single tablet ...

Merck reports positive results from phase 3 trial of once-daily, oral, two-drug, single-tablet regimen of Doravirine/Islatravir in treatment-naïve adults with HIV-1 infection ...

Data indicates mounting numbers among adults, highlighting hurdles for service systems, requiring renewed strategies, ...

But the rollout is now being wielded as a political tool. What that “America First” slogan actually means for global health ...

Learn about the risk of getting HIV from anal sex, vaginal sex, oral sex, and shared needles, plus the most effective ways to ...

Cryo-EM revealed HIV-1 integrase’s distinct structures as it shifts between its two roles of DNA integration and RNA-binding.

Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...

The report shows that before the freeze, 87 per cent of Nigeria’s HIV budget depended on US government support.

Ahead of World AIDS Day on which is commemorated annually on 1 December, UNAIDS is launching a new report on Tuesday 25 ...